Fadi Haddad/X
Nov 14, 2023, 01:06
Fadi Haddad: P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT
Fadi Haddad, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shared the following post by The Lancet Haematology, on Twitter adding the following:
“P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT:
- Similar 4y OS: 26% vs 30%
- Better safety profile of DAC-10
Combos with VEN & targeted therapies are moving the field forward
Clad-LDAC-VEN very effective & safe in older pts Tapan Kadia”
Quoting The Lancet Haematology:
“NEW: 10-day decitabine vs 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial”
Source: Fadi Haddad/Twitter and The Lancet Haematology/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 17:53
Apr 19, 2025, 17:17
Apr 19, 2025, 17:01
Apr 19, 2025, 16:44
Apr 19, 2025, 16:23